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Abstract: Tumor cells harboring stem-like/cancer stem cell (CSC) properties have been identified and
isolated from numerous hematological and solid malignancies. These stem-like tumor cells can persist
following conventional cytoreductive therapies, such as chemotherapy and radiotherapy, thereby
repopulating the tumor and seeding relapse and/or metastasis. We have previously shown that
natural killer (NK) cells preferentially target stem-like tumor cells via non- major histocompatibility
complex (MHC) restricted mechanisms. Here, we demonstrated that the proteasome inhibitor,
bortezomib, augments NK cell targeting of stem cell-like tumor cells against multiple solid human
tumor-derived cancer lines and primary tissue samples. Mechanistically, this was mediated by the
upregulation of cell surface NK ligands MHC class I chain-related protein A and B (MICA and MICB)
on aldehyde dehydrogenases (ALDH)-positive CSCs. The increased expression of MICA and MICB
on CSC targets thereby enhanced NK cell mediated killing in vitro and ex vivo from both human
primary tumor and patient-derived xenograft samples. In vivo, the combination of bortezomib and
allogeneic NK cell adoptive transfer in immunodeficient mice led to increased elimination of CSCs
as well as tumor growth delay of orthotopic glioblastoma tumors. Taken together, our data support
the combination bortezomib and NK transfer as a strategy for both CSC targeting and potentially
improved outcomes in clinical cancer patients.
Keywords: natural killer cells; bortezomib; cancer stem cell; ALDH; sarcoma; brain tumor;
pancreatic cancer
1. Introduction
Originally identified based on the ability of a small, phenotypically pure population of cancer
cells to form heterogeneous tumors composed of diverse cell progeny, stem-like tumor cells have
been identified in numerous solid and hematological cancer types [1]. The first published reports of
tumor initiating cells were based on the isolation of CD34+ hematopoietic cells from blood samples
of acute myeloid leukemia patients, which, once purified based on cell surface phenotype, were able
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to engraft into severely immunodeficient mice, differentiate into phenotypically distinct progeny,
and demonstrate self-renewal capabilities [1,2]. Follow up studies have identified stem-like tumor
cells in multiple mammalian tumor types, including human breast cancer, head and neck cancers,
brain cancer, pancreatic cancer, melanoma, sarcoma, multiple myeloma, colon cancer, liver cancer,
and kidney cancers, among others [3]. Although cancer stem cells (CSCs) have been challenging to
phenotypically categorize, multiple studies have relied on the expression and/or co-expression of
specific cell surface and intracellular proteins in a variety of tumor models. However, a major challenge
in the study of CSCs is the lack of a reliable, uniform, and practical marker system which can be used
to identify and phenotype CSCs across different tumor types [4]. The activity and expression of the
family of intracellular enzymes known as aldehyde dehydrogenases (ALDH) is one of a select few
cellular constituents that has been found to reproducibly correlate with a CSC phenotype across tissue
types [5,6].
In fact, ALDH activity has been shown to identify stem-like tumor cells with CSC behavior in
diverse solid tumor types [7–13]. In addition, the clinical relevance of ALDH expression has been
evaluated in several scenarios, and ALDH expression has been found to correlate with worse overall
survival for patients with non-small cell lung cancer, breast cancer, and ovarian cancer [14]. For instance,
it has been described that ALDH1A1 and ALDH1B1, two members of the ALDH gene superfamily
composed of 17 functional genes and three pseudogenes, are associated with hematopoietic stem cells
and cancer stem cell functions, respectively [15,16]. Taken together, these data reinforce the significance
of therapeutically targeting ALDH positive cancer cells (which are often resistant to conventional
cytotoxic cancer treatments) as well as tumors with high ALDH expression.
Recently, our lab has demonstrated that immunotherapy using isolated, expanded, and activated
human natural killer (NK) cells is able to selectively target human CSCs, including those with an
ALDHbright phenotype [17]. While NK cells are known to possess the ‘innate’ ability to kill tumor cell
targets in a major histocompatibility complex (MHC)-unrestricted fashion, it is the expression of stress
ligands, such as MHC class I chain-related protein A and B (MICA and MICB), and apoptosis-inducing
receptors, such as Death receptor (DR) 5, that appear to drive CSC susceptibility to NK cell targeting
and killing. Overall, NK cell activity and cytotoxic function is tightly regulated by the balance of
activating and inhibitory signals received upon engagement with a target cell [18,19], and CSCs have
been found to express higher levels of these activating receptors compared to non-CSCs within the
same tumor [17,20].
Bortezomib is a first-generation proteasome inhibitor used clinically for the treatment of patients
with multiple myeloma and mantle cell lymphoma. One of the proposed mechanisms of action of
the drug is the potentiation of NK cell killing towards target cells. Indeed, bortezomib has been
demonstrated by our lab and others to promote NK cell lysis of target cells via the upregulation of
death receptors on the tumor cell surface and through the promotion of caspase activation [21–25].
However, it is unclear how bortezomib may influence the susceptibility of ALDHbright cells to NK cell
killing. While we have previously shown that radiotherapy is capable of sensitizing these cells to NK
cell killing via Natural Killer group 2, member D (NKG2D) mechanisms, the mechanism of action of
bortezomib, its relatively short half-life, and its ability to be administered systemically may be more
attractive and efficacious as a strategy to augment NK function in a clinical setting.
In this report, we show that ALDHbright CSCs from several solid tumor types, including human
primary tumors are sensitive to induction of NK ligands MICA and MICB following bortezomib
treatment. Additionally, we show that bortezomib treatment leads to an enrichment of ALDHbright
cells. Moreover, bortezomib pre-treatment significantly sensitizes ALDHbright cells to NK cell killing
both in vitro and in vivo, leading to improved elimination of CSCs and significant tumor growth delay.
Together, these results suggest that this immuno-oncology combination using NK cells may prove
useful as a mean to target CSCs and improve oncologic outcomes in otherwise refractory malignancies.
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2. Results
2.1. Bortezomib Treatment Enriches for ALDHbright Tumor Cells from Several Solid Tumor Types
Given our experience using radiotherapy as a way to enrich for stem-like tumor cells, we first
sought to evaluate the impact of bortezomib exposure on the ALDH phenotype of tumor cells in vitro.
Following 24, 48, or 72 h incubation, we evaluated cytotoxic effects of bortezomib on human U87
(glioblastoma), SW982 (synovial sarcoma), and PANC-1 (pancreatic adenocarcinoma) cell lines. We
observed a similar decrease in cell viability in a dose and time dependent manner in SW982 and PANC-1
cell lines, while U87 showed a modest resistance to the cytotoxic effects of bortezomib (Figures 1a–c
and S1a–f). Based on these observations, we then decided to assess ALDH expression following a 48-h
incubation in media containing 0, 10, 20, and 40 nM of bortezomib. In these experiments (Figure 1d–i),
we observed significant enrichment in ALDHbright cells, particularly in U87 and SW982.
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Figure 1. Dosing effect of bortezomib on ALDHbright cells. The anti-viability effects of bortezomib
treatment were assessed in glioblastoma (U87) (a), synovial sarcoma (SW982) (b), and pancreatic
adenocarcinoma (PANC-1) (c) cells. U87 (d,e), SW982 (f,g), and PANC-1 (h,i) cells were analyzed by
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flow cytometry after 48 h of bortezomib for the frequency of live cells with an ALDHbright
phenotype. The fold change of viable ALDHbright and ALDHdim cells was compared using flow
cytometry for U87 (j), SW982 (k), and PANC-1 (l) cell lines. DEAB: Representative gating for the
N,N-diethylaminobenzaldehyde control selective inhibitor of aldehyde dehydrogenase isoenzymes.
Experiments were repeated three-five times, including a minimum of three technical replicates for each
experiment. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001).
We then sought to determine if the enrichment in ALDHbright cells following bortezomib treatment
was due to direct effects of bortezomib on the ALDHbright population, due to effects on the ALDHdim
population, or both. Following incubation with bortezomib for 48 h, cells were analyzed by flow
cytometry for the frequency and number of ALDHbright and ALDHdim cells in culture (Figure S1g–l).
In these experiments, we observed a differential response of ALDHbright and ALDHdim cells to
bortezomib treatment. For instance, in U87 cells, we observed increased frequency and numbers
of ALDHbright cells (Figures 1d,e,j and S1g,j). We observed similar effects in SW982 cells with a
significant increase in ALDHbright numbers in ALDHbright cells at both 10 and 20 nM concentrations,
respectively, and by frequency at 10, 20, and 40 nM (Figures 1f,g,k and S1h,k). In SW982 cells, we also
noted a modest decrease in the frequency of the ALDHdim population following bortezomib treatment
(Figures 1k and S1k). In contrast, the PANC-1 cell line (Figure 1h,i,l) showed an increase in frequency
in the ALDHbright subpopulation across all treatment conditions; however, these differences were
only significant at 20nM of bortezomib. In the PANC-1 cell line, we did not observe an increase
by numbers in the ALDHbright subpopulation (Figure S1i). However, we observed a dose response
represented by a fold change decrease in the fraction of ALDHdim cells relative to ALDHbright cells
in PANC-1(Figure 1l) and a decrease by cell number for this particular subpopulation (Figure S1l).
Interestingly, even though we observed ALDH enrichment effect across the different cell lines tested,
the 20 nM concentration seemed to be the optimal concentration where ALDH enrichment occurred
while at 40 nM of bortezomib greater anti-viability effects occurred in both sub-populations. Taken
together, these data suggest that the mechanism of ALDHbright enrichment is the result of a greater
resistance to the cytotoxic/cytostatic effects of bortezomib among ALDHbright versus ALDHdim cells
across cancer cell lines.
2.2. Bortezomib Increases the Expression of Stress Ligands and Death Receptors on both ALDHbright and
ALDHdim Cells
Bortezomib has been shown to induce the expression of death receptors such as DR5 on the surface
of both mouse and human tumor cell lines [26]. Therefore, we next evaluated if bortezomib would
induce differential expression of death receptors and stress ligands on ALDH subpopulations in our
cancer cell lines. Bortezomib significantly upregulated the expression of DR5, Fas, and MICA/B on both
ALDHbright and ALDHdim U87 cells in vitro (Figure 2a–f). Similarly, we observed a significant increase
in DR5, MICA/B, and Fas expression in SW982 cells following bortezomib treatment (Figure 2g–l).
For each protein examined, bortezomib induced a dose-dependent increase in protein expression with
20 nM of bortezomib showing the highest level of upregulation as quantified by median fluorescence
intensity (MFI) level by flow cytometry. Additionally, we compared the mRNA expression of MICA,
MICB, and ULBP1 in U87 and SW982 cells after 48 and 72 h of bortezomib exposure (Figure 2m–o).
U87 cells increased expression of the both MICA and MICB at 48 h and 72 h post-treatment. However,
we observed ULBP1 to be more than two-fold upregulated only at a dose of 40 nM at 72 h post-treatment
(Figure 2o). In SW982 cells, we observed a similar upregulation of MICA and MICB gene expression
at both 48 and 72 h time points post-treatment (Figure 2p,q). Interestingly, the expression of ULBP1
increased by at least two-fold in SW982 cells at 48 h at doses of 10 and 20 nM, however, gene expression
levels decreased at 72 h. In the 40 nM treatment group, the expression was a consistent significant
increase in ULBP1 expression >2-fold baseline at both 48 and 72 h. Given reports that bortezomib
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treatment decreases MHC class I expression in ALDHbright cells in multiple myeloma and thereby
sensitizes myeloma to NK killing [27], we then investigated the expression of MHC class I in our
glioblastoma and sarcoma cancer lines after bortezomib exposure. Although we observed increased
expression of MHC class I in U87 cells treated at 10 and 20 nM doses for 48 h with exception between
0 and 10 nM in the ALDHdim subpopulation (Figure S2a), no significant differences were observed
in SW982 (Figure S2b). It has been reported previously that the absence or downregulation of MHC
class I molecules by tumor cells could be associated with escape mechanisms from T cell targeting [28].
In this regard, upregulation of MHC class I expression on U87 cells and maintenance on SW982 cells
may represent an inducible pathway that cancer cells utilize to resist immune pressure from NK
or T cells depending on the dominant cellular/local conditions. Regardless, our data demonstrate
that upregulation of NK ligands is a prevalent phenomenon among tumor cells after bortezomib
exposure. Although this upregulation occurred in both ALDHbright and ALDHdim subsets, the increase
in ALDHbright cell numbers and frequencies after bortezomib exposure suggests that expression
of these stress ligands is relevant to NK targeting of these resistant cells after cytotoxic/cytostatic
drug therapies.
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stress ligands in U87 and SW982 cells stratified by ALDHbright and ALDHdim expression. Overlaid
histograms are representative for the expression of DR5, Fas, and MICA/B. Bar graphs were generated
from median fluorescence intensity (MFI) calculations for each stated condition comparing the MFI
from ALDHbrigh and ALDHdim populations in each of the treatments, respectively. Expression of
MICA, MICB, and ULBP1 in U87 (m–o) and SW982 cells (p–r) was assessed by qPCR after 48 and 72 h
of bortezomib treatment, respectively. Dotted lines indicate a two-fold expression threshold consistent
with significant upregulation. Experiments were repeated three–five times including a minimum of
three technical replicates for each testing condition. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p <
0.0001).
2.3. U87 ALDHbright Subpopulations Exhibit Increased Expression of Cancer Stem Cell-Related Markers
Compared to ALDHdim Subpopulations
Next, we sought to investigate gene signature differences between the ALDHbright and ALDHdim
sorted tumor subpopulations. Therefore, we sorted, then expanded and phenotyped ALDHbright
and ALDHdim cells from U87 parent cells. We observed that after short term culture over 1–2
weeks, we were able to maintain relatively pure ALDHbright and ALDHdim populations (Figure 3a,b).
The frequency of the ALDHdim subpopulation in the sorted and expanded ALDHdim subpopulation
remained at approximately 14% with an MFI of 2537 ± 125, while in the ALDHbright population the
frequency of ALDHbright cells remained at approximately 74% with an MFI of 8570 ± 545. In the
unsorted parent cells, the population frequency of the ALDHbright population was approximately
24% with an MFI of 3195 ± 18 (Figures 3a,b and S3a). Using these sorted and short-term expanded
ALDH subpopulations, we then isolated RNA and performed a PCR array, analyzing 88 unique target
genes associated with cancer stem cell signatures. After analysis, we observed that the ALDHbright
subpopulation demonstrated increased expression of ABCB5, ALDH1A1, DDR1, ERBB2, ITGA2, ITGA6,
KLF4, NOTCH1, PROM1, SOX2, and THY1 genes. In contrast, expression of MERTK1, and TWIST2
was found to be downregulated (Figure 3c). Interestingly, the majority of the genes that we found to
be upregulated in the ALDHbright subpopulation have been reported as markers involved not only in
CSCs in general, but particularly in brain tumor CSCs [29–31].
Bortezomib Affects Expression of Cancer Stem Cell-Related Genes and MICA/B in both ALDHbright
and ALDHdim Subpopulations
We then evaluated the effect of bortezomib on sorted and expanded populations after 48 h of
bortezomib at 20 nM compared to untreated controls (0 nM). When comparing the untreated ALDHdim
subpopulation to 20 nM treated cells, we observed an increase in expression of SOX2, ALDH1A1,
DKK1, KLF4, PROM1, ERBB2, and ABCB5 among others. Additionally, we observed a downregulation
of THY1 and MUC1 among others (Figure 3d). When comparing treated to untreated ALDHbright
cells, we observed an upregulation of ALDH1A1, CD44, IL8, DKK1, EGF, MERTK, MYC, NANOG,
NFKB1, TWIST2, ZEB1 and downregulation of THY1 and MUC1 (Figure 3e). When comparing treated
ALDHbright to ALDHdim populations, we observed an upregulation of THY1, ITGA2, and ITGA6 and
a downregulation of KLF4 and LIN28B (Figure 3f). Interestingly, these data suggest that THY1 and
ITGA6 are likely directly associated with ALDH expression independent of treatment while ALDH1A1,
IL8, and DKK1 are potentially upregulated in response to bortezomib treatment in both ALDHbright
and ALDHdim subpopulations. It is important to note that these results may be further clarified
by improving the sorting purity of both ALDHbright and ALDHdim subpopulations, as certain gene
signatures may be affected by residual ALDHbright cells in the ALDHdim enriched subpopulation
(extended gene analysis results for this particular assay are shown in Figure S3f). Of note, we observed
increased ALDH1A1 expression in response to bortezomib treatment in both ALDHbright and ALDHdim
subpopulations similar to ALDH2 (Figure S3b,c). This particular finding may suggest that not only
is ALDH1A1 upregulated in response to bortezomib, but also other gene members of the aldehyde
Cancers 2019, 11, 85 7 of 20
dehydrogenase superfamily such as ALDH2. Additionally, we analyzed the expression of MICA
and MICB in response to bortezomib, observing that both ALDHbright and ALDHdim populations
exhibited upregulation of NKG2D ligands (Figure S3d,e). These data agree with our previous findings
in unsorted cells where both subpopulations showed increased expression of MICA and MICB. The
biological significance of NKG2D ligand upregulation in both ALDHbright and ALDHdim subsets
warrants further exploration, although our data suggest that ALDHdim cells are eliminated at higher
rates by NK cells compared to ALDHbright cells in response to bortezomib treatment. This may
be unrelated to expression of NK ligands; however, it may also represent the effects of differential
shedding of NK ligands by ALDHdim subsets via ADAM17 and other proteases.
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increased expression of ALDH by MFI in enriched ALDHbright sorted cells and decreased expression
of ALDH by MFI on sorted ALDHdim cells compared to unsorted cells and DEAB control. Bar graphs
generated from qPCR arrays show differential expression of cancer stemness-associated markers in
sorted subpopulations. (c) ALDHdim compared to ALDHbright untreated cells, (d) ALDHdim untreated
(0 nM) compared to ALDHdim treated with 20 nM bortezomib, (e) ALDHbright untreated (0 nM)
compared to ALDHbright treated with 20 nM bortezomib, (f) ALDHdim treated compared to ALDHbright
treated with 20 nM bortezomib. Dotted lines indicate a two-fold expression threshold consistent with
significant upregulation.
2.4. Bortezomib Enriches for ALDHbright Cells from Human Primary Glioblastoma and Breast Tumor
Next, we assessed the effects of bortezomib on primary human tumor samples as the use of
continually passaged cell lines has been called into question, particularly in studies of the genetic and
epigenetic factors which impact tumor heterogeneity and CSC behavior. Therefore, to better validate
the relevance of our findings, we assessed freshly excised tumor samples from patients undergoing
surgical resection. We analyzed a human primary glioblastoma tumor and a human primary breast
cancer, which were mechanically and enzymatically dissociated and then plated in standard cell culture
medium as a single cell suspension for 24 h. Treatment of tumor cells from a primary brain tumor
with 20 nM bortezomib led to a significant increase in the proportion of ALDHbright cells (Figure 4a,b).
Additionally, we observed a significant increase in the expression by MFI of DR5, and MICA/B,
but not Fas as previously observed with the U87 cell line (Figure 4c). Similar results were observed
with tumor cells from a primary breast cancer surgically removed and then treated with 0, 5, 10, and
20 nM bortezomib ex vivo after single cell digestion (Figure 4d–g). In this patient-derived specimen,
we observed an increase in the number of ALDHbright cells when the cells were treated with bortezomib
compared to the untreated control (Figure 4f). We observed a significant decrease in cell numbers
on the ALDHdim-treated cells at 5 and 10 nM of bortezomib (Figure 4f). Flow cytometric analysis
revealed that DR5, Fas and MICA/B expression was increased on ALDHbright cells after bortezomib
treatment (Figure 4h), although effects were observed in ALDHdim cells as well. Additionally, we
observed an increase in the mRNA expression levels of Smoothened Frizzled Class Receptor (SMO),
a hedgehog transducer that has been previously associated with tumorigenesis in a dose dependent
manner (Figure 4i) [32]. We then evaluated the expression levels of MICA (Figure 4j) and MICB
(Figure 4k) genes. We found that MICA was significantly upregulated in cells treated with 10 and 20nM
of bortezomib while MICB was significantly upregulated at 20 nM of bortezomib. Taken together,
these data suggest that enrichment of ALDHbright stem-like tumor cells and the simultaneous increase
in the cell surface expression of DR5, MICA, and MICB following bortezomib treatment occurs in
primary patient-derived samples in addition to immortal cancer cell lines grown in adherent cell
culture conditions. Given the increasing attention to the spontaneous tumors in outbred dogs as a
model to facilitate translation of novel immunotherapy approaches [33,34], we also evaluated primary
dog sarcomas treated ex vivo with bortezomib. Similar to human spontaneous tumors, we observed
that bortezomib pre-treatment enriched for both the numbers and frequencies of ALDHbright tumor
cells and that bortezomib demonstrated increasing anti-viability effects at doses up to 40 nM, leading
to enrichment in the number of ALDHbright CSCs (Figure S4).
Cancers 2019, 11, 85 9 of 20
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of ALDHbright cells on all bortezomib treated cells ex vivo. (f,g) Bar graph shows the number of
ALDHbright and ALDHdim cells in BR-1416 cells after bortezomib for 24 h. (h) Representative histogram
shows the expression by MFI of DR5, Fas and MICA/B in ALDHbright and ALDHdim on BN-0469.
(i–k) qPCR of BR-1416 cells treated with bortezomib after 24 h shows a significant dose dependent
increase in expression of Smoothened Frizzled Class Receptor (SMO), MICA, and MICB. (* = p < 0.05,
** = p < 0.01, *** = p < 0.001).
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2.5. ALDHbright Cells Are Sensitized to NK Cell Killing following Bortezomib Pre-Treatment In Vitro
Based on our previous work demonstrating that NK cells have the ability to lyse stem-like tumor
cells, including ALDHbright cells in vitro and in vivo, we next assessed whether NK cytotoxicity against
ALDHbright cells would be augmented following bortezomib pretreatment. First, we expanded and
activated human NK cells extracted from human peripheral blood mononuclear cells (PBMC) followed
by activation and expansion for 14–21 days. After 14 days in culture, we evaluated the phenotype of
expanded NK cells and found comparable expression of CD56 and NKG2D in NK cells expanded from
three different donors (Figure 5a). SW982 sarcoma cells were pretreated with medium containing 0 or
20 nM concentration of bortezomib for 24 h. Following bortezomib treatment, cells were washed with
fresh medium and then co-cultured with activated allogeneic NK cells at an effector to target ratio
of 0.125:1. After bortezomib pretreatment and NK co-culture, we observed a significant reduction in
the frequency of ALDHbright cells (Figure 5b,d). In addition to the reduction in ALDHbright frequency,
we observed reductions in the total number of viable ALDHbright cells after bortezomib and NK
co-culture (Figure 5e).
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and 100 IU/mL rhIL-2. (b) SW982 and (c) U87 cells were pretreated with or without 20 nM bortezomib
for 24 h prior to co-culture with activated human NK cells at an Effector: Target (E:T) ratio of 0.125:1 for
12 h. Representative flow cytometry showed increased NK killing of ALDHbright cancer cells after 20
nM bortezomib. The frequency and number of ALDHbright SW982 (d,e) and U87 (f,g) cells in different
co-culture conditions were assessed. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001).
We then assessed the effects of bortezomib-mediated sensitization to NK cell killing on U87 cells
and observed a similar pattern of enhanced cytotoxicity (Figure 5c,f). In fact, the combination of
bortezomib pretreatment and NK cell exposure led to a dramatic and statistically significant reduction
in the frequency of ALDHbright cells remaining after 24 h (Figure 5f), as well as a reduction in the
overall numbers of ALDHbright cells (Figure 5g). Therefore, we concluded that bortezomib is not only
capable of enriching for ALDHbright stem-like tumor cells, but also sensitizes those cells to NK cell
cytotoxicity, presumably due to the bortezomib-induced enhanced expression of NK ligands.
2.6. The Combination of NK Cells and Bortezomib Leads to Reduced Stem-Like Tumor Cells In Vivo and
Promotes Tumor Regression
Based on these data, we then sought to assess the efficacy of bortezomib plus NK adoptive
transfer in vivo. First, we tested if the augmented ALDHbright tumor cell killing we observed in vitro
could be replicated in vivo, where the three-dimensional (3D) nature of the tumor and issues of drug
and NK cell accessibility to the tumor could alter the effectiveness of either treatment alone or the
combination. To do so, we implanted subcutaneous U87 tumors into the flanks of immunodeficient
NSG mice (Figure 6a). When tumors reached 5–7 mm in diameter, mice were injected with 20 µg
of intraperitoneal (i.p.) bortezomib ×3 and/or activated NK cells, and tumors were assessed for
changes in ALDHbright cells following in vivo treatment (Figure 6b). Similar to the results observed
in vitro, bortezomib alone led to a significant increase in the frequency of ALDHbright cells (Figure 6c),
with little effect on the total number of ALDHbright cells (Figure 6d) within the tumor. In contrast,
the combination of bortezomib and NK cells administered intra-tumorally 24 h after bortezomib
treatment led to a significant decrease in both the frequency and total number of ALDHbright cells
recovered (Figure 6c,d).
Next, we assessed the therapeutic potential of this combination therapy in NSG mice bearing
orthotopic intracranial U87 xenografts. Briefly, luciferase transfected tumor cells were implanted into
the brain using stereotactically guided instrumentation. Following tumor implantation, mice were
treated with i.p. bortezomib as before. Thereafter, a single injection of 106 activated allogeneic human
activated NK cells were administered intratumorally. Tumor size was monitored via bioluminescence,
and quantification was assessed starting from the date of bortezomib treatment. Importantly,
the administration of either NK cells alone or bortezomib alone had a noticeable effect on tumor
size six days after treatment (Figure 6e). However, by 25 days after treatment, the anti-tumor effects of
bortezomib monotherapy and NK cell monotherapy, but not combination therapy, were lost. Mice that
received the combination of bortezomib and NK cells demonstrated a significant reduction in tumor
size, which persisted to day 25 (Figure 6g), compared to untreated mice (Figure 6f). Additionally,
the overall tumor growth was significantly delayed for the combination therapy group as compared
to all other groups. We assessed the tumor burden of orthotopic U87 xenografts by bioluminescence
over time showing significantly less bioluminescence in the bortezomib plus NK treated mice at all
time points starting at day 15 (Figure 6h). These results suggest that the combination therapy could act
to reduce tumor growth over time by limiting the potential for ALDHbright stem-like tumor cells to
continue to seed the tumor niche with non stem-like cells.
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to assess tumor burden based on bioluminescence. (e) Representative bioluminescent images of mice
are shown for each time point. Representative MRI images of xenografts from an untreated mouse
(f), and bortezomib and NK cell treated mouse (g) at day 25 are also shown with evidence for notable
decrease in tumor size post combination treatment. The needle tract for intra-tumoral NK injection is
marked by the arrow and the tumor is marked by the white star, which is nearly completed resolved.
(h) We assessed the tumor burden of orthotopic U87 xenografts by bioluminescence over time (n = 3
mice/group). (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001).
3. Discussion
In these studies, we demonstrated the presence of a subpopulation of ALDHbright, stem-like
tumor cells, which appear relatively resistant to the direct cytotoxic effects of the proteasome inhibitor
bortezomib, but demonstrate upregulation of NK ligands and death receptors, which allow for additive
anti-tumor effects when bortezomib pre-treatment is followed by NK immunotherapy in vitro and
in vivo. Notably, the ALDHbright cells, which survived following bortezomib treatment, appeared
to become sensitized to NK cell mediated killing through the concomitant upregulation of surface
molecules, which facilitated NK cell mediated cytotoxicity, such as MICA/B, DR5, and Fas.
While other groups have demonstrated that the combination of bortezomib and NK cells is
effective in pre-clinical studies, our study is one of the first to highlight the ability of this combination
to target CSCs, especially in solid tumor models. In addition, we assessed the anti-tumor effects
in vivo, which provide further support of the potential for this combination to be clinically meaningful.
Although the combination is under investigation in clinical trials (primarily in the post bone marrow
transplantation scenario), it is important to recognize the impact of the dosing and timing of both
treatments on the potential success of this strategy. We have previously demonstrated that bortezomib
is cytotoxic to NK cells in vitro, and as such, the timing of this combination therapy must be carefully
planned to avoid bortezomib-mediated NK cell inhibition in vivo [17,35]. Additionally, in our in vivo
model, NK cells were administered directly into the tumor site following systemic bortezomib
administration. One of the major limitations to the efficacy of adoptive NK cell therapy is the limited
tumor-infiltrating capacity that is observed with NK cell adoptive transfer in vivo. The use of an
intralesional injection strategy aims to circumvent this limitation, allowing highly activated NK cells to
interact directly in the tumor niche; however, this strategy may not be widely applicable in the setting
of diffuse metastatic disease. For this reason, glioblastoma and other locally aggressive tumors may be
particularly suited to NK immunotherapy strategies, since intra-tumoral delivery of NK cells is more
feasible in these situations.
Yet, despite the efficacy observed in our model system, several caveats must be considered
before this approach can be successfully translated to the clinic. First, it is unclear if and how CSC
selection could occur following this therapy. It is possible that within the CSC niche, subsets of CSCs
exist that could evade NK cell detection, either by harboring an inherent resistance to the sensitizing
effects of bortezomib, or by altering the expression of various factors that could regulate NK cell
responses. Indeed, many of the tumor-NK cell escape mechanisms that have been proposed could also
be applicable to CSCs, such as heightened secretions of TGF-β and IL-10 [36–40].
Additionally, it remains to be determined how and why ALDHbright cells can resist the apoptotic
effects of bortezomib. Previous studies suggested that the Wnt/β-catenin signaling pathway can
stimulate tumor cells with resistance mechanisms against bortezomib. Indeed, bortezomib has been
found to lead to increased β-catenin accumulation in tumor cells, and β-catenin has separately been
shown to drive the expression of ALDH in radio-resistant prostate cancer cells [41,42]. Therefore,
increased expression of β-catenin as a response to bortezomib treatment may simultaneously stimulate
ALDH expression in CSCs and promote resistance. Interestingly, previous studies have also found
that the selective ALDH inhibitor, disulfiram, can overcome bortezomib resistance in AML cells [2].
Similarly, in proliferating, sub-confluent, endothelial cell cultures, it has been shown that proteasome
inhibition can induce apoptosis at a concentration 340-fold lower than that required in quiescent
cells, suggesting that proteasome inhibition may affect tumor growth by preferentially inhibiting
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proliferating cells/non-CSCs [43]. In a related publication, the same group demonstrated that
proteasome inhibition induced apoptosis in proliferating cells while showing evidence of protective
effects in some quiescent cells [44]. Increased ALDH levels in CSCs may have a direct effect in
resistance to the cytotoxic effects of bortezomib, especially as cellular proliferation versus quiescence is
considered a cardinal feature in distinguishing CSCs from non-CSCs [15,16]. Additionally, our studies
suggest that the ALDHbright population validates the CSC phenotype based on the increased expression
of brain cancer stem cells genes such as ALDH1A1, ITGA6, THY1, PROM1, and SOX2, as reported
previously. Moreover, our studies showed an increase in the expression of multiple other genes
associated with CSC phenotype in U87 cells following bortezomib treatment, including IL8, DKK1,
and SMO, which have all been reported to be involved in stemness pathways as well as increased drug
resistance [29–31].
Ultimately, while the mechanisms of ALDH-mediated resistance mechanisms remain unclear, our
in vitro and in vivo data suggest that the combination of bortezomib and NK cell therapy may represent
an attractive strategy to target residual CSCs that may persist and/or seed relapse in a variety of solid
malignancies after standard cytotoxic treatments. It is important to consider potential barriers that may
arise while using autologous or allogeneic derived, expanded, and activated human NK cells. Some of
the limitations may include hyporesponsiveness and survival of NK cells when adoptively transferred
into cancer patients due to the notable change from an in vitro environment with maximal cytokine
stimulation to an in vivo environment less replete in cytokine support. To maintain infused NK cells
in an activated state in vivo in our models, we injected an IL-15-producing plasmid as described in
our prior publications. Although clinical experience in human cancer patients has shown favorable
responses with intravenous rhIL-2, concerns exist regarding the potential immunosuppressive effects
of rhIL-2, including induction of regulatory T cells (Tregs) and activation-induced cell death of immune
effector cells. In contrast, likely because of the trans-presentation of IL-15:IL-15Rα complexes rather
than solubilization of the cytokine for signaling, IL-15 has negligible if any effects on Tregs and
provides anti-apoptotic signals to CD8+ T cells. Therefore, there is increasing attention on strategies
combining IL-15 and NK immunotherapy to maximize anti-tumor effects and limit NK hyporesponsive
following adoptive transfer. However, other causes of NK cell hyporesponsiveness after in vivo transfer
include inhibitory signaling produced by the tumor microenvironment, such as increased production
of inhibitory cytokines, deficient recruitment into the tumor site, and deficient migration and/or
engraftment of NK cells into the tumor [45]. In order to overcome some of these limitations, some
investigators have proposed a selection of expanded NK cell subpopulations expressing CXCR3,
which increased migration toward solid tumors or genetic overexpression of CXCR2 to promote tumor
homing as has been demonstrated in a renal cell carcinoma model [46–48].
Ultimately, further studies are needed to understand intrinsic resistance mechanisms, routes of
NK administration, and in vivo activation strategies in order to optimally apply NK cells as a cancer
therapeutic. Combination therapy with proteasome inhibitors such as bortezomib may be one such
strategy given the CSC targeting effects.
4. Materials and Methods
4.1. Tumor Cell Lines
U87MG, PANC-1 and SW982 were purchased from American Type Culture Collection
(ATCC, Manassas, VA, USA) and propagated in the culture medium recommended by ATCC.
Fresh de-identified primary human tumor samples (BN-0469 primary glioblastoma and BC-1154
primary breast cancer) were obtained immediately following surgical resection from the UC Davis
Comprehensive Cancer Center Biorepository. Human tumors were mechanically and enzymatically
dissociated using a 60-min incubation of 1 mg/mL collagenase-IV and 0.1 mg/mL DNAse I at 37 ◦C.
For all experiments, primary cells were used within 48 h of isolation. Consent was obtained from all
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patients before tissue procurement under the auspices of the Institutional Review Board of UC Davis
(Protocol # 218204).
4.2. NK Cell Isolation
Human NK cells were isolated from leukoreduction system (LRS) chambers obtained from
healthy donors (BloodSource, Sacramento, CA, USA). LRS chambers were back-flushed with PBS and
lymphocytes were isolated following high-speed centrifugation with Lymphocyte Separation Medium
(Cellgro, Manassas, VA, USA) as per manufacturer’s instructions. Lymphocytes were then counted
using a Z Series Coulter Counter (Beckman Coulter, Indianapolis, IN, USA) and re-suspended at 5
× 107 cells/mL with an additional 1000 patient-matched red blood cells per lymphocyte. NK cells
were isolated from the above samples using a RosetteSep™ Human NK Cell Enrichment Cocktail
(STEMCELL Technologies, Vancouver, BC, Canada) as per manufacturer’s instructions. This protocol
typically yielded >95% CD45+/CD56+/CD3− cells.
4.3. NK Cell Expansion and Activation
The artificial antigen presenting cell line K562 clone 9.mbIL-21 was used as a feeder cell source
to promote expansion and activation of primary human NK cells in vitro. These cells were kindly
provided by Dr. Dean Lee (Nationwide Children’s Hospital, Columbus, OH, USA). Freshly isolated
NK cells were co-cultured with K562 clone 9.mbIL-21 cells as previously described [49]. Briefly, freshly
isolated NK cells were mixed with irradiated K562 clone 9.mbIL-21 at a ratio of two K562 clone
9.mbIL-21 cells per NK cell in medium containing 100 IU/mL recombinant human IL-2 (Biological
Resources Branch, NCI, Frederick, MD, USA). NK cells were counted and re-suspended in fresh IL-2
supplemented medium every two–three days. Every seven days, NK cells were collected, counted,
and plated with freshly irradiated feeder cells at a ratio of one K562 clone 9.mbIL-21 per NK cell.
NK cells were grown in RF10 complete medium in upright T-75 flasks each containing no more than
40 mL total volume. All NK cells were used between days seven and 21 of expansion.
4.4. Bortezomib Treatment Assays
For bortezomib assays cells were plated in 10 mL of standard culture medium at cell densities of
1 × 106 for U87 and SW982; or 0.5 × 106 for PANC-1 into T-25 culture flasks. Bortezomib (Selleckchem,
Houston, TX, USA) was then added to cell culture medium at the indicated concentrations (0 nM refers
to untreated controls). At indicated time points, all live and dead cells were harvested by incubating
cells with TrypLE (Thermofisher, Waltham, MA, USA) for 5 min at 37 ◦C, followed by neutralization
and washing with fresh medium and used for further analysis or experimental assays. Cell viability
was assessed by trypan blue exclusion using the TC20 automated cell counter (Bio-Rad, Hercules,
CA, USA).
4.5. Flow Cytometric Cytotoxicity Assay
1 × 105 tumor cells were plated in triplicate with the indicated ratios of NK cells in a 96-well plate
for 24 h. After 24 h, plates were washed and analyzed using the ALDEFLUOR™ assay, as previously
described [17,49]. All flow cytometric killing assays were additionally stained with CD45 to exclude
NK cells from analysis and Fixable Viability Dye™ (eBioscience, San Diego, CA, USA) to exclude
dead cells.
4.6. Flow Cytometry and Cell Sorting
Brilliant Violet 711 anti-CD45 (HI30), PE-CY7 anti-NKG2D (1D11) PerCPef710 anti-HLA-ABC
(W6/32), APC anti-MICA/B (6D4), PECy7 anti-Fas (DX2), Brilliant Violet 605 anti-CD56 (HCD56),
and PE DR5 (DJR2-4) were purchased from BioLegend (San Diego, CA, USA). Fixable Viability Dye
455UV and ef780 were purchased from eBioscience. Stained samples were acquired on an LSR Fortessa
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with High-throughput system attachment (HTS) (BD Biosciences, San Jose, CA, USA) and analyzed
with FlowJo version 10 software (TreeStar, Ashland, OR, USA). ALDEFLUOR™ expression (STEMCELL
Technologies, Vancouver, BC, Canada) was determined according to manufacturer’s instructions and
with a DEAB (Diethyl Amino Benzaldehyde) control well for each Effector: Target ratio and for each
individual condition tested accordingly. Cells were kept at 4 ◦C until analysis and were analyzed in
small batches to prevent leakage due to changes in temperature. For fluorescence-activated cell sorting
(FACS) sorting, cells were stained with ALDEFLUOR similar to flow cytometry analysis, and tubes
were submerged on ice during and after sorting. About 2% of the brightest ALDEFLUOR cells and 5%
of the dimmest ALDEFLUOR cells were gated and sorted into 500 µL of FBS using a Becton Dickinson
Influx cell sorter (BD Biosciences, San Jose, CA, USA). After sorting, cells were washed with fresh
medium and transferred to T-25 culture flasks and cultured under standard cell culture conditions
until cells reached 80–90% confluency. Thereafter, cells were harvested, counted, and cryopreserved
for future experiments.
4.7. Tumor Models
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were given tumors through subcutaneous
or intracranial injections. For subcutaneous models, mice received 106 U87 cells in 100 µL PBS
in the rear flank. For the intracranial model, anesthetized NSG mice were injected with 5 × 104
luciferase-transfected U87 cells orthotopically 2.5 mm left and 1 mm anterior to the bregma. A 10 µL
Hamilton syringe was plunged 3.5 mm deep, then withdrawn 1 mm (to 2.5 mm) using a Just for Mice™
stereotaxic instrument (Braintree Scientific, Inc., Braintree, MA, USA) and 2 µL of total volume was
injected. All experimental protocols were approved by the UC Davis Institutional Animal Care and
Use Committee (Protocol #19621).
4.8. Hydrodynamic IL-15 Plasmid Delivery
For in vivo studies, we injected an IL-15-producing plasmid, which we have used previously to
sustain the viability of NK cells in an immunodeficient host [50]. Expression of IL-15 in this plasmid
is driven via the cytomegalovirus (CMV) promoter and human enhancer filamentation 1 (HEF-1)
enhancer. Mice are injected via high pressure tail vein injection of 1.6 mL of PBS containing 10 µg of
plasmid in 4–6 seconds. This hydrodynamic IL-15 gene delivery was always administered 24 h before
NK cell injections.
4.9. In Vivo Imaging
Following implantation, tumor burden was assessed every three-four days. Animals were
anesthetized with inhaled isoflurane and injected with 3 mg cold D-luciferin. After 5 min anesthetized
mice were placed into an IVIS-Spectrum imaging station (Caliper Life Sciences, Waltham, MA, USA)
and bioluminescence was recorded. Alternatively, mice were imaged by T2-weighted Magnetic
resonance imaging (MRI) on a Biospec 7T (Bruker, Billerica, MA, USA) in collaboration with the UC
Davis Center for Molecular and Genomic Imaging.
4.10. RNA Extraction and qPCR
Total RNA was extracted using the RNeasy plus mini kit (Qiagen, Venlo, Netherlands). RNA
concentrations were then quantified using a Qubit4 Fluorometer (Invitrogen, Carlsbad, CA, USA) and
RNA integrity was assessed using the Agilent TapeStation (Agilent, Santa Clara, CA, USA) Total RNA
was reverse transcribed using iScript, and qPCR was performed using CFX384 (Bio-Rad, Hercules,
CA, USA). Reference genes used for normalization were GAPDH and HPRT1. Data were analyzed
using the Bio-Rad CFX manager software (Bio-Rad) and expressed as fold change. PrimePCR array
(Bio-Rad) was performed following manufacturer’s instructions and recommendation using a CFX96
from the same vendor and data analysis performed using CFX Maestro (Bio-Rad).
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4.11. Statistics
Statistical analysis was performed using Prism software (GraphPad Software Inc., San Diego,
CA, USA). Data were expressed as mean ± (SEM) unless otherwise stated. For analysis of three or
more groups, analysis of variance (ANOVA) tests were performed with a Bonferroni or Tukey post-hoc
test, when appropriate. Analysis of differences between two normally distributed test groups was
performed using the Student’s t-test. If p < 0.05, p-values were considered statistically significant.
5. Conclusions
These studies provide insight into the sensitization effect on CSCs caused by the proteasome
inhibitor bortezomib, as this treatment yields an enrichment of an ALDHbright subpopulation in
different human cell lines, including PANC-1, SW982, and U87, as well as primary human breast
and brain tumor cells. Moreover, bortezomib treatment results in increasing expression of the tumor
necrosis factor (TNF) family receptors DR5 and Fas as well as the stress induced ligands MICA/B,
which are targeted by the NKG2D receptor expressed by human activated NK cells. Taken together,
these studies provide important information in favor of the use of NK cell adoptive transfer as an
adjuvant to existing chemotherapeutic approaches utilizing bortezomib in chemorefractory tumors
such as glioblastoma and sarcomas.
Further work is required to better elucidate optimal dosing and timing of bortezomib when used
in combination with NK cell adoptive transfer. The optimal techniques for expanding and activating
human NK cells remains an area of great interest given the potential therapeutic benefits for treatment
of solid malignancies and successful elimination of CSC subpopulations.
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